Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.

Bobu AM, Turliuc S, Cucu AI, Onofriescu A, Dascalu CG, Costea CF, Patrascanu E, Morosan AP, Haisan A, Filip CN, Covali R, Buzduga CM, Botnariu G, Enache IIC

Journal of clinical medicine18 May 2025Cited by 1 (Europe PMC)

PMID40429530PMCIDPMC12111957DOI10.3390/jcm14103536PepBankPUB-40429530

Download PDF PubMedAsk about this study

Jump to 8 results

Summary

Background: Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist administered subcutaneously once a week, developed through recombinant DNA technology, and prescribed as an add-on to diet and exercise for managing type 2 diabetes mellitus in adults. In several clinical trials, once-weekly dulaglutide has demonstrated reductions in cardiovascular risk associated with diabetes, as well as improvements in glycemic control and weight reduction. The scope of this study was to evaluate the effect of dulaglutide 1.5 mg on glycemic control, weight management, and LDL-cholesterol levels in patients with uncontrolled type 2 diabetes mellitus. Methods: We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg. We monitored fasting plasma glucose and glycated hemoglobin (HbA1c) at baseline and at 6, 12, and 24 months after initiating dulaglutide treatment. Weight, body mass index, and LDL-cholesterol were assessed at baseline and after 24 months of dulaglutide therapy. Results: Treatment with dulaglutide resulted in significant improvements in fasting plasma glucose and HbA1c after 6 months (p p p < 0.001). A significant weight reduction was observed after 24 months of dulaglutide therapy (-3.3 kg; p < 0.001). In addition, we observed a significant reduction in LDL-cholesterol after 24 months (p < 0.001). Conclusions: Our data demonstrate that dulaglutide 1.5 mg significantly improves glycemic control, reduces body weight, and lowers LDL-cholesterol in Romanian patients with inadequately controlled type 2 diabetes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide treatment was linked to reduced fasting plasma glucose at 6 months versus baseline.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower fasting glucose at 6 months than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose at 6 months
Study
n = 55
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide resulted in significant improvements in fasting plasma glucose and HbA1c after 6 months (p p p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We monitored fasting plasma glucose and glycated hemoglobin (HbA1c) at baseline and at 6, 12, and 24 months after initiating dulaglutide treatment.
Summary · context
We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg.
Show in the study text Report a problemFND-4042953001
02HumanObservational studyEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide treatment was linked to reduced fasting plasma glucose at 12 months versus baseline.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower fasting glucose at 12 months than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose at 12 months
Study
n = 55
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 12 monthsAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide resulted in significant improvements in fasting plasma glucose and HbA1c after 6 months (p p p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We monitored fasting plasma glucose and glycated hemoglobin (HbA1c) at baseline and at 6, 12, and 24 months after initiating dulaglutide treatment.
Summary · context
We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg.
Show in the study text Report a problemFND-4042953002
03HumanObservational studyEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide treatment was linked to reduced fasting plasma glucose at 24 months versus baseline.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower fasting glucose at 24 months than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose at 24 months
Study
n = 55
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 24 monthsAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide resulted in significant improvements in fasting plasma glucose and HbA1c after 6 months (p p p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We monitored fasting plasma glucose and glycated hemoglobin (HbA1c) at baseline and at 6, 12, and 24 months after initiating dulaglutide treatment.
Summary · context
We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg.
Show in the study text Report a problemFND-4042953003
04HumanObservational studyEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide treatment was linked to reduced HbA1c at 6 months versus baseline.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower HbA1c at 6 months than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c at 6 months
Study
n = 55
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide resulted in significant improvements in fasting plasma glucose and HbA1c after 6 months (p p p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We monitored fasting plasma glucose and glycated hemoglobin (HbA1c) at baseline and at 6, 12, and 24 months after initiating dulaglutide treatment.
Summary · context
We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg.
Show in the study text Report a problemFND-4042953004
05HumanObservational studyEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide treatment was linked to reduced HbA1c at 12 months versus baseline.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower HbA1c at 12 months than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c at 12 months
Study
n = 55
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 12 monthsAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide resulted in significant improvements in fasting plasma glucose and HbA1c after 6 months (p p p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We monitored fasting plasma glucose and glycated hemoglobin (HbA1c) at baseline and at 6, 12, and 24 months after initiating dulaglutide treatment.
Summary · context
We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg.
Show in the study text Report a problemFND-4042953005
06HumanObservational studyEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide treatment was linked to reduced HbA1c at 24 months versus baseline.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower HbA1c at 24 months than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c at 24 months
Study
n = 55
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 24 monthsAs given in this study (human).
Source sentences
Summary
Treatment with dulaglutide resulted in significant improvements in fasting plasma glucose and HbA1c after 6 months (p p p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We monitored fasting plasma glucose and glycated hemoglobin (HbA1c) at baseline and at 6, 12, and 24 months after initiating dulaglutide treatment.
Summary · context
We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg.
Show in the study text Report a problemFND-4042953006
07HumanObservational studyEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide treatment was linked to a significant weight reduction of -3.3 kg at 24 months.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower weight at 24 months than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight at 24 months
Study
n = 55
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg · 24 monthsAs given in this study (human).
Measurements
Weight change
−3.3 kg
24 months versus baseline
Source sentences
Summary
A significant weight reduction was observed after 24 months of dulaglutide therapy (-3.3 kg; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Weight, body mass index, and LDL-cholesterol were assessed at baseline and after 24 months of dulaglutide therapy.
Summary · context
We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg.
Show in the study text Report a problemFND-4042953007
08HumanObservational studyEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide treatment was linked to lower LDL cholesterol at 24 months versus baseline.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower LDL cholesterol at 24 months than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLDL cholesterol at 24 months
Study
n = 55
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg · 24 monthsAs given in this study (human).
Source sentences
Summary
In addition, we observed a significant reduction in LDL-cholesterol after 24 months (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Weight, body mass index, and LDL-cholesterol were assessed at baseline and after 24 months of dulaglutide therapy.
Summary · context
We retrospectively reviewed the medical records of 55 patients with inadequately controlled type 2 diabetes mellitus who were on oral antidiabetic agents and insulin, and who were additionally treated with dulaglutide 1.5 mg.
Show in the study text Report a problemFND-4042953008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.